About this study
Some people with acute lymphoblastic leukemia or lymphoma receive a medicine called asparaginase. This medicine helps treat cancer. Sometimes, asparaginase can cause a painful problem called pancreatitis. The pancreas is an organ behind the stomach that helps digest food and control blood sugar. Pancreatitis happens when the pancreas becomes swollen and irritated. This can cause belly pain, nausea, vomiting, fever, and a fast heartbeat. In severe cases, pancreatitis can be life threatening.
When pancreatitis happens, doctors may need to stop or change the cancer treatment. Right now, there are not many ways to prevent this problem. Current treatments for pancreatitis only help with the symptoms. They do not fix the cause.
This study tests a new experimental medicine called CM4620. Researchers want to see if CM4620 can make pancreatitis less severe. They also want to find out if CM4620 is safe and what dose works best for children and young adults.
In the study, patients get CM4620 through a vein using an IV for 4 days. Treatment starts soon after pancreatitis begins. The plan is to follow the patients for several weeks and up to about 4 months to watch for side effects, safety, how much drug the body handles, and signs that it helps.
This research may help future patients have fewer severe side effects from cancer treatment. It could also teach doctors more about how to protect the pancreas during therapy.
Eligibility overview
- Up to 21 years old
- Has acute lymphoblastic leukemia/ lymphoma
- Has acute pancreatitis that started within the past 36 hours after receiving asparaginase treatment within the last few weeks
- Able to get medicine through an IV (a vein)